moxifloxacin + polymyxin + trimethoprim

This antibiotic regimen is utilized as a standard postoperative prophylactic treatment for patients undergoing pars plana vitrectomy for rhegmatogenous retinal detachment, specifically within clinical protocols at the Massachusetts Eye and Ear Infirmary. The regimen typically involves the administration of moxifloxacin 0.5% ophthalmic solution, with a combination of polymyxin B and trimethoprim serving as an alternative for patients with known allergies to fluoroquinolones. Moxifloxacin is a fourth-generation fluoroquinolone that inhibits bacterial DNA synthesis by targeting DNA gyrase and topoisomerase IV. Polymyxin B is a cyclic lipopeptide that disrupts the bacterial outer membrane by binding to lipopolysaccharides, while trimethoprim is a pyrimidine inhibitor of dihydrofolate reductase, blocking the production of tetrahydrofolic acid. Together, these agents provide broad-spectrum coverage against both Gram-positive and Gram-negative pathogens to prevent postoperative endophthalmitis.

Brand names

VigamoxPolytrimMoxeza

Other names

moxifloxacin + polymyxin B + trimethoprimmoxifloxacin 0.5% or polymyxin/trimethoprim